ESR1 and neoplasm: The association between ER and RTK/MAPK alterations and the PAM50 subtype suggests that some RTK/MAPK oncogenic drivers in HR + /HER2- MBC may induce resistance to endocrine therapy by switching the tumor towards an ER pathway-independent transcriptional state.